Efung Capital
Efung Capital is a venture capital and private equity firm based in Shenzhen, China, founded in 2007. The firm specializes in early-stage and growth capital investments, particularly in the healthcare and life science sectors, focusing on biopharmaceuticals, high-end medical devices, and original drugs. Additionally, Efung Capital explores opportunities in technology, media, telecommunications, environmental protection, and new materials. The firm typically invests between RMB 5 million to RMB 50 million per transaction and aims to achieve exits through various channels, including initial public offerings, stock transfers, mergers, acquisitions, and management buyouts. With a strong research team and a track record of successful investments in more than 20 premium enterprises, Efung Capital has garnered recognition as a leading institution in the biomedical industry, enhancing its influence within the medical and life science sectors.
Past deals in Rotterdam
Harbour BioMed
Series B in 2020
Harbour BioMed is a biotechnology company focused on discovering and developing therapeutics for cancer and inflammatory diseases. Established in 2016 with operations in Shanghai, Cambridge, and Rotterdam, the company leverages its proprietary transgenic mouse platforms to generate fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb), enabling the development of differentiated compounds such as bi-specific and multi-specific antibodies. Harbour BioMed collaborates strategically with various institutions and companies, including The Wistar Institute, WuXi Biologics, and Vir Biotechnology, to advance its pipeline of therapeutics targeting autoimmune diseases, dry eye disease, COVID-19, and other indications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.